Screen-detected invasive cervical carcinoma and its clinical significance during the introduction of organized screening

Size: px
Start display at page:

Download "Screen-detected invasive cervical carcinoma and its clinical significance during the introduction of organized screening"

Transcription

1 DOI: /j x Epidemiology Screen-detected invasive cervical carcinoma and its clinical significance during the introduction of organized screening A Herbert, a Anshu, a M Gregory, a SS Gupta, b N Singh a a Histopathology Department, Southampton University Hospitals Trust, Southampton, UK and b Department of Community Medicine, Mahatma Gandhi Institute of Medical Sciences, Sevagram, India Correspondence: Dr A Herbert, Department of Histopathology, Southampton University Hospitals Trust, Southampton, UK. amanda.herbert@kcl.ac.uk Accepted 4 September Published Online 7 April Objective To assess the clinical significance of screen-detected cancer compared with symptomatic cervical cancer during the introduction of organized screening. Study design Screen-detected and symptomatic cancers were analysed according to International Federation of Obstetrics and Gynecology stage and histological type of cancer and age of women during four 3-year periods. Setting Southampton and South West Hampshire (SSWH). Population Women resident in SSWH registered with invasive cervical carcinoma between 1985 and Methods Screen-detected and symptomatic cancers were defined on the basis of clinical information obtained at the time of diagnosis and recorded together with date of diagnosis, age group, histology and cytology results. Data were held for analysis on an anonymous spreadsheet. Main outcome measures Incidence of screen-detected and symptomatic cancers per women; association between route to diagnosis, age group, stage of cancer and screening history during four 3-year periods. Results Of 382 cancers, 256 were symptomatic, 78 screen-detected fully invasive and 48 screen-detected microinvasive. Incidence of symptomatic cancers fell from 13.0 to 6.4 per total female population (P = ), and there was a trend towards screendetected cancers as a proportion of all cancers (P = 0.002). By the latest period of the study ( ), the likelihood of cancers being screen-detected was strongly associated with younger age groups (P = 0.001). Screen-detected fully invasive cancers were significantly less likely (P = 0.001) to be diagnosed at stage II or above (16.6%) compared with symptomatic cancers (63.3%). Women with screen-detected microinvasive cancers were significantly more likely (P < 0.001) to have been screened within 5 years (83.3%) than screen-detected fully invasive cancers (60.2%) or symptomatic cancers (33.6%). Conclusion Screen-detected cancers were more likely to be diagnosed at an earlier stage, in younger women and in women who had previously been screened and became relatively more frequent as symptomatic cancers declined. Keywords Cervical cancer incidence, cervical screening, interval cancers, invasive cervical cancer audit, screen-detected cancer. Please cite this paper as: Herbert A, Anshu, Gregory M, Gupta S, Singh N. Screen-detected invasive cervical carcinoma and its clinical significance during the introduction of organized screening. BJOG 2009;116: Introduction Since the introduction of the NHS Cervical Screening Programme (NHSCSP) in 1988, the incidence of cervical cancer has fallen from 18.4 in 1988 to 8.8 in 2005, 1 despite an increasing risk in women born since ,3 Before 1988, screening had been largely opportunistic in younger age groups and quality control was known to be poor. 4 A national audit of invasive cervical cancer reported that cytological screening was less effective at preventing frankly invasive cancer in women younger than over the age of 40 years. 5 Microinvasive carcinomas were excluded from that analysis as they were likely to be screen-detected; however, the authors found that it was not possible to identify screendetected fully invasive cancers from routine data in centrally held records. 5 A national audit is now under way to investigate all cases and stages of invasive cervical cancer, 6 but the criteria for defining screen-detected cancers have yet to be established. This study has been carried out to investigate the significance of the route to diagnosis of cervical cancer since a preliminary report of the same data set, led by one of the authors, 854 ª 2009 The Authors Journal compilation ª RCOG 2009 BJOG An International Journal of Obstetrics and Gynaecology

2 Significance of screen-detected cervical cancer indicated that screen-detected cancers in general (microinvasive and fully invasive) were more likely to be stage I than symptomatic cancers and were associated with a better 5-year survival. 7 This finding applied to adenocarcinomas as well as squamous cell carcinomas. 8 There are few studies on screendetected cervical cancers as such, although cancers in previously screened women have been shown to be diagnosed at an earlier stage than those in unscreened women. 9,10 We revisited the data collected in the Southampton and South West Hampshire (SSWH) study because we believe that it may be relevant to the national audit of invasive cervical cancer that is now under way. We intend to use these data as a baseline for the audits of cervical cancers that are currently in progress in Southampton and Guy s & St Thomas NHS Foundation Trust as part of the NHSCSP audit. Our findings may also be relevant to programmes currently being introduced in Europe in populations like SSWH that have already been partially screened opportunistically. In this study, registrations of invasive cancer in four consecutive 3-year periods are described (from to ), which represent screening before, during and after the implementation of the NHSCSP in SSWH. The incidence of cervical cancer in SSWH declined more or less in parallel with that of England as a whole during the period of the study. 8,11 We have compared symptomatic, screen-detected fully invasive and screen-detected microinvasive cancers with respect to the 3-year period of the study, age group, stage, histological diagnosis and screening history. The complete details of screening histories are presented in further detail in a second paper. 12 Population, subjects and methods Study area and population The study population comprised the female population in SSWH. That area was estimated by the Office for Population Censuses and Surveys to have an average total female population of in 1986, in 1989, in 1992 and in 1995, the mid-points of the four periods of the study. 11 Women aged between 20 and 64 years were eligible for cervical screening, and a centralized call and recall system was implemented during the second period ( ), although screening uptake had increased steadily during the previous decade (unpublished observations). Data collection Invasive cervical cancers in women residents of SSWH were retrieved from the computerized histology records at Southampton General Hospital, local cancer registry data, Wessex Radiotherapy and Oncology Units and requested from other NHS hospitals in adjacent districts. All women were validated and checked for duplication and miscoding. The details of data collation have been outlined in a previous paper. 7 Study group The study group composed of 382 women residents of SSWH in whom invasive cervical cancer was diagnosed between 1985 and Cancers were grouped according to the age of the woman at the time of cancer diagnosis into four age bands: 20 34, 35 39, and 65 years and older. Women 65 years and older were not invited for screening. For purposes of analysis, the cancers were grouped into four consecutive 3-year periods depending upon the time of cancer diagnosis: , , and Histological type and stage of cancer The histological type of carcinoma was recorded as squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, undifferentiated carcinoma or type unknown. Stage was recorded for all except three cancers, which were only known to be invasive. Stage IA1 squamous carcinomas were classified as those with a depth of invasion less than 3 mm and lateral extent less than 7 mm using the revised International Federation of Obstetrics and Gynecology (FIGO) classification. Until 1996, stage IA2 cancers were not identified separately and any women in the study were included with IB cancers. Although there are no accepted criteria for stage IA adenocarcinoma, the same criteria for depth and extent of invasion were used. Route to diagnosis Women with invasive cancer were categorized as screendetected if the cancer was found as a direct result of an abnormal smear reported during a routine screening test and the woman was asymptomatic. This included microinvasive and fully invasive cancers. Symptomatic cancers were found as a result of investigation of symptoms. Route to diagnosis, which was initially assessed from clinical data on cytology request forms, histology reports and referral letters from the general practitioners, was confirmed, in cases of doubt, by contacting the general practitioner by letter. Two women were difficult to classify, but as they consistently claimed to be symptom free at the time of diagnosis, they were included in the screen-detected group. The diagnosis was made as a direct result of an invitation for a cervical smear in these women. One was called for screening, but a smear was not taken because of vaginismus: a mass was noticed on examination and cervical cancer subsequently diagnosed. One was found to have a procidentia when called for a routine smear, which was negative. Hysterectomy revealed microinvasive carcinoma. In 17 women with screen-detected cancers, minor gynaecological symptoms like heavy periods or discharge were noted on direct questioning after the diagnosis had been ª 2009 The Authors Journal compilation ª RCOG 2009 BJOG An International Journal of Obstetrics and Gynaecology 855

3 Herbert et al. made. Some degree of cervical abnormality, ranging from erosion or cervicitis to clinical suspicion of cancer, was noted in 24 women at the time of smear taking. Incidence of cancer Incidence has been calculated for each 3-year period by calculating one-third of the total number of cancers per women of all ages in the population at the mid-point of each time period. Similarly, incidence has been calculated for symptomatic, screen-detected fully invasive and screendetected microinvasive cancers, respectively. Screening histories Women were classified as no previous cytology record, not screened within 5.5 years prior to cancer diagnosis or screened within 5.5 years prior to cancer diagnosis (described in this study as interval cancers). That interval was chosen because, until 1993, screening coverage was calculated at an interval of 5.5 years to take account of delays between invitation and reporting. 13 The screening history excluded tests carried out within 6 months of diagnosis, which were either abnormal smears on the basis of which diagnosis was made (screen-detected cases) or smears taken during investigation of symptoms (symptomatic cases). Statistical analysis Chi-square test was used as a test of inference to compare difference between proportions. Chi-square for trend was used to test significance of trend of proportions across study years. Statcalc calculator in the EPI INFO 6 software was used for calculation of these tests. Results Incidence and trends according to route to diagnosis Of the 382 carcinomas, 256 (67.0%) were symptomatic, 78 (20.4%) screen-detected fully invasive and 48 (12.6%) screen-detected microinvasive carcinomas (Table 1). There were 108 carcinomas registered in , 102 in , 102 in and 70 in Incidence of all cancers per women fell from 16.8 in to 10.4 in , but this fall took place almost entirely in the fourth period of the study (Table 1 and Figure 1). Incidence of symptomatic cancers fell steadily from 13.0 to 6.4 per , which was highly significant (P = ). As the numbers of symptomatic cancers fell, there was a significantly increased trend in the proportion of screen-detected cancers compared with all cancers (chi-square for trend 9.046, P = 0.002) during the study period. This trend was significant for screen-detected microinvasive cancers (chi-square for trend , P < 0.001) but Table 1. Incidence per total female population of symptomatic and screen-detected cancers according to 3-year time period and numbers of women according to age band Total female population at mid-point of 3-year period Symptomatic (256) years (30) years (67) years (55) years (104) Incidence per , all ages Screen-detected fully invasive (78) years (13) years (33) years (25) years (7) Incidence per , all ages Screen-detected microinvasive (48) years (9) years (27) years (10) years (2) Incidence per , all ages All cancers (382) years (52) years (127) years (90) years (113) Incidence per , all ages (n) 5 total to not for screen-detected fully invasive cancers alone (chisquare for trend 0.077, P = 0.781). Route to diagnosis according to age band Fifty-two cancers were seen in women aged years, 127 aged years, 90 aged years and 113 aged 65 years and older. There was no fall in numbers of cervical cancers in women aged (Table 1), but there was a significant trend towards screen-detected cancers in that age band (chisquare for trend 5.835, P = 0.015). Women aged years, who comprised the largest group overall and 52.8% (142/269) in age bands eligible for screening, showed an increase in screen-detected microinvasive cancers in the third period of the study (Figure 1). In women aged years, there was 856 ª 2009 The Authors Journal compilation ª RCOG 2009 BJOG An International Journal of Obstetrics and Gynaecology

4 Significance of screen-detected cervical cancer Incidence per Screen-detected fully invasive Symptomatic Screen-detected microinvasive All cancers Figure 1. Trends in incidence of symptomatic and screen-detected cervical cancer ( ). a steady decline in the total numbers, but an increase in screen-detected fully invasive cancers was noted in the second period of the study. In women above the age of 65 years, 92% of cancers were symptomatic, and this did not change significantly throughout the time period of the study. By the last period of the study ( ), there was a strong association between the likelihood of cancers being screen-detected and the younger groups. Screen-detected cancers composed 75.0% (9/12) of cancers in women aged years, 50.0% (11/22) in women aged years, 33.0% (5/15) in women aged years and 9.5% (2/21) in women aged 65 years and older (P < 0.001). Route to diagnosis and FIGO stage Of the 382 women with carcinomas, 54 were stage IA1 (microinvasive), 153 stage IB, 84 stage II, 62 stage III and 26 stage IV. The stage was unknown in three women, although they were known to be fully invasive cancers (Table 2). Cases of stage II and above were symptomatic in 160 (83.3%) of 172 women. Although similar proportions of stage IB cases were symptomatic (57.5%) and screen-detected fully invasive cancers (42.4%), significantly more symptomatic cancers were stage II or above (162/256; 63.3%) compared with screen-detected fully invasive cancers (13/78; 16.7%) (P < 0.001). Route to diagnosis and histological type There were 281 women with squamous carcinomas and 78 adenocarcinomas. Eight carcinomas of either undifferentiated or unknown histological type were included with the squamous carcinomas for purposes of analysis, while 15 adenosquamous carcinomas were combined with the adenocarcinomas. Of squamous carcinomas, 69.2% were symptomatic, while 30.7% were screen-detected. While 60.2% of adenocarcinomas were symptomatic, 39.8% were screendetected. There was no significant difference in the percentages of adenocarcinomas among symptomatic cancers (21.9%), screen-detected fully invasive cancers (33.3%) and screen-detected microinvasive cancers (22.9%). Route to diagnosis and screening histories There was no record of previous cytology in 148 women (38.7%), among whom 132 (89.2%) had symptomatic cancers. Sixty-one women (15.9%) had been screened more than Table 2. Route to diagnosis of invasive cervical cancer according to FIGO stage, histological type and screening history Total cancers Symptomatic Screen-detected fully invasive Screen-detected microinvasive FIGO stage IA IB II III IV Invasive Total 382 (100) 256 (67.0) 78 (20.4) 48 (12.6) Histological type Squamous cell carcinoma/carcinoma, not otherwise specified Adeno/adenosquamous carcinoma Total 382 (100) 256 (67.0) 78 (20.4) 48 (12.6) Screening history No previous cytology Screened more than 5.5 years before diagnosis Screened within 5.5 years Total 382 (100) 256 (67.0) 78 (20.4) 48 (12.6) ª 2009 The Authors Journal compilation ª RCOG 2009 BJOG An International Journal of Obstetrics and Gynaecology 857

5 Herbert et al. 5.5 years before the diagnosis of cancer, and 173 (45.2%) had been screened in the preceding 5.5 years (excluding referral or symptomatic tests within 6 months of cancer diagnosis). Although women who had been screened within 5.5 years were equally likely to have screen-detected (49.7%) as symptomatic (49.3%) cancers, there was a strong association between the route to diagnosis and the likelihood of the woman having been screened within 5.5 years; thus, 86 of 256 (33.6%) of symptomatic cancers, 47 of 78 (60.2%) of the screen-detected fully invasive cancers and 40 of 48 (83.3%) of screen-detected microinvasive cancers were in women who had been previously screened (interval cancers) (P < 0.001). Discussion This study shows the clinical relevance of route to diagnosis of cervical cancers in several ways. First, screen-detected cancers represented an increasing proportion of cancers, while the incidence of symptomatic cancers steadily declined. Screendetected cancers were also more likely to be diagnosed at an early stage even when fully invasive. In addition, as organised screening became established, screen-detected cancers were increasingly associated with younger age groups and were more likely to be seen in previously screened women. Route to diagnosis is not obvious from the central screening records used in England, which is in agreement with Sasieni et al. 5 Although it might be feasible to decide which women were screen-detected from the date of invitation, many women have tests opportunistically either before or after the due date. For instance, in SSWH, 74.7% of eligible women were screened within 3.5 years, by their own request or invited by their general practitioners, even though the official recall interval at that time was 5 years. 14 The NHSCSP defines screen-detected cancers as cancers which were detected after a diagnostic process that began with a cytology test taken up to three months before the test due date or up to six months after the test was due. 6 However, apart from women who chose to have tests early or later, we feel that these criteria should not exclude interval cancers or lapsed attenders, many of which, in our experience, are screen-detected. Especially with the advent of multidisciplinary meetings, it is usually relatively easy to obtain information and segregate screen-detected from symptomatic cancers. However, it might be better to separate screen-detected from not screen-detected cases, as the latter could include doubtful cases; that was our intention at the time of the audit, but our study shows that it can occasionally be difficult to decide the route to diagnosis. There are very few reports in the existing literature that have compared screen-detected cervical cancers as such with symptomatic cancers. However, Sigurdsson et al. 9 reported that women who had attended the cervical screening programme fared significantly better than those who had never attended. Young women had a significantly better prognosis than older women. The prognostic effect of screening was mainly attributed to the more favourable distribution of early stages and younger age at diagnosis among the screened women. After all the analyzed parameters had been adjusted, the non-attenders still had poorer prognosis. Pretorius et al. 10 found that women who had abnormal cervical smears had better disease-free survival than those who presented with symptoms of abnormal vaginal bleeding or pain. Our study shows that there was a significant trend towards screendetected cancers across the period of the study, even in the youngest women aged years. In the last period of the study, as many as 75% of cancers in that age band were screen-detected. Benedet et al. 17 have said that age, per se, represents a valuable prognostic factor but is an independent prognostic factor only for women with stage I cancers. We suggest that the strong association between screen-detected cancers and younger age groups accounts for the better prognosis reported in young women with cervical cancer. We also believe that detection of microinvasive cancer is a positive outcome of screening that should be taken into account, especially in the current climate of necessarily conservative management of young women. That these cancers are increasingly found in young women and are seldom found on the first cytology test may be an argument against delaying the first screening invitation to age 25 years. 18 Our study showed that cancers were most frequent in women aged years, which is consistent with an increased risk in women born since ,3 Women in that age band with cancers diagnosed between 1985 and 1996 would have been born between 1966 and That age band held 16 of 24 (75%) screen-detected microinvasive cancers in the third period of the study when there was a peak in the incidence of that category. We found an interesting association between screen-detected cancers and their likelihood of being interval cancers. Interval cancers were progressively more frequent with screen-detected microinvasive cancers compared with screen-detected fully invasive cancers and with the latter group compared with symptomatic cancers. Thus, the peak in screen-detected microinvasive cancers in the third period of our study would have involved a high proportion of interval cancers. This is considered in more detail in a separate study, 12 which examines the reasons why cancers develop in previously screened women. We have demonstrated the clinical importance of cervical cancers being screen-detected rather than being symptomatic, especially once organised screening is established. These cancers are more likely to be diagnosed at an earlier stage in younger women and in women who have previously been screened. Disclosure of interest None of the authors have interests that conflict with the study. 858 ª 2009 The Authors Journal compilation ª RCOG 2009 BJOG An International Journal of Obstetrics and Gynaecology

6 Significance of screen-detected cervical cancer Contribution to authorship A.H. conceived and carried out the initial 12-year audit while employed as Lead Cytopathologist at Southampton University Hospitals Trust (SUHT). Anshu while a Commonwealth Fellow at GSTFT helped write the paper and prepared the tables and graphs from the spreadsheet. S.S.G. carried out the statistical analysis. M.G. led the Southampton cytology laboratory throughout the time of the study and collaborated in collecting the information about screening at that time. N.S. is now the Lead Cytopathologist at SUHT and helped with this study and was co-author of the previous study of the same data set when it was transferred to an anonymous spreadsheet. Details of ethics approval Approval for this audit was gained at the time the project was started in January 1992 when a 3-year grant was successfully applied for and Catherine Breen appointed as a research assistant. Funding Wessex Cancer Trust and Cansearch, which was the campaigning arm of the British Society for Clinical Cytology, jointly provided the grant that enabled the original project to be set up and carried out. Guy s & St Thomas Charity provided a grant for A.H. to carry out the final analysis of the data set as a baseline for a GSTT cervical cancer audit. Acknowledgements We thank Catherine Breen, the research assistant who set up the original audit database at Southampton General Hospital and Jennifer Smith, Director at that time of Wessex Cancer Intelligence Unit who provided population and coverage data for a previous study of the full data set referred to in the text. j References 1 Quinn MJ, Babb PJ, Jones J, Baker A, Ault C. Cancer Registrations of Cancer Cases and Deaths in England and Wales by Sex, Age, Year, Health Region and Type of Cancer (CD-ROM). London: Office for National Statistics, Bray F, Carstensen B, Moller H, Zappa M, Zakelj MP, Lawrence G, et al. Incidence trends of adenocarcinoma of cervix in 13 European countries. Cancer Epidemiol Biomarkers Prev 2005;14: Bray F, Loos AH, McCarron P, Weiderpass E, Arbyn M, Moller H, et al. Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening. Cancer Epidemiol Biomarkers Prev 2005;14: Cancer of the cervix: death by incompetence (editorial). Lancet 1985;2: Sasieni P, Adams J, Cuzick J. Benefit of cervical screening at different age groups: evidence from the UK audit of screening histories. Br J Cancer 2003;89: NHS Cervical Screening Programme. Audit of Invasive Cervical Cancers. NHSCSP Publication no. 28. Sheffield: Herbert A, Breen C, Bryant TN, Hitchcock A, Macdonald H, Millward- Sadler GH, et al. Invasive cervical cancer in Southampton and South West Hampshire: effect of introducing a comprehensive cervical screening programme. J Med Screen 1996;3: Herbert A, Singh N, Smith JAE. Adenocarcinoma of the uterine cervix compared with squamous cell carcinoma: a 12-year study in Southampton and South-West Hampshire. Cytopathology 2001;12: Sigurdsson K, Hrafnkelsson J, Geirsson G, Gudmundsson J, Salarsdottir A. Screening as a prognostic factor in cervical cancer: analysis of survival and prognostic factors based on Icelandic population data Gynecol Obstet 1991;43: Pretorius R, Semrad N, Watring W, Fotheringham N. Presentation of cervical cancer. Gynecol Oncol 1991;42: Wessex Regional Health Authority. Office of Population Censuses and Surveys Mid Year Population Estimates Herbert A, Anshu, Gregory M, Gupta SS, Singh N. Invasive cervical cancer audit: a relative increase in interval cancers while coverage increased and incidence declined. BJOG 2009;116: Department of Health. Summary data from Form KC53 (Adult Screening Programme). Cervical cytology : part one. 14 Herbert A, Stein K, Bryant TN, Breen C, Old P. Relation between the incidence of invasive cervical cancer and the screening interval: is a five year interval too long? J Med Screen 1996;3: Herbert A, Bryant TN, Campbell MJ, Smith J. Investigation of the effect of occult invasive cancer on the progress towards successful cervical screening. J Med Screen 1998;5: desouza NM, Soutter WP, McIndoe GA, Gilderdale DJ, Krausz T. Stage 1 cervical cancer: tumour volume by magnetic resonance imaging of screen-detected versus symptomatic lesions. J Natl Cancer Inst 1997; 89: Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, Heintz AP, et al. Carcinoma of the cervix uteri. Int J Gynaecol Obstet 2003;83 (Suppl 1): Herbert A, Holdsworth G, Kubba AA. Cervical screening: why young women should be encouraged to be screened. J Fam Plann Reprod Health Care 2008;34:21 5. ª 2009 The Authors Journal compilation ª RCOG 2009 BJOG An International Journal of Obstetrics and Gynaecology 859

NHSCSP proposals for cervical screening intervals. Comments and recommendations of Council of the British Society for Clinical Cytology

NHSCSP proposals for cervical screening intervals. Comments and recommendations of Council of the British Society for Clinical Cytology NHSCSP proposals for cervical screening intervals Comments and recommendations of Council of the British Society for Clinical Cytology The following paper is written on behalf of BSCC Council to express

More information

How invasive cervical cancer audit affects clinical practice

How invasive cervical cancer audit affects clinical practice How invasive cervical cancer audit affects clinical practice Referring to NHSCSP and EU guidelines and audits in Southampton and London Amanda Herbert Guy s & St Thomas Foundation NHS Trust How invasive

More information

Keywords Cytology-screening, statistics-epidemiological surveys.

Keywords Cytology-screening, statistics-epidemiological surveys. DOI: 10.1111/j.1471-0528.2007.01467.x www.blackwellpublishing.com/bjog Epidemiology An examination of the role of opportunistic smear taking in the NHS cervical screening programme using data from the

More information

Northern Ireland Cervical Screening Programme

Northern Ireland Cervical Screening Programme Northern Ireland Cervical Screening Programme ANNUAL REPORT & STATISTICAL BULLETIN 2010-2011 1 Report produced by : Quality Assurance Reference Centre, PHA Date of Publication: September 2012 2 Contents

More information

NATIONAL CERVICAL CANCER SCREENING PROGRAMME Monitor 2017

NATIONAL CERVICAL CANCER SCREENING PROGRAMME Monitor 2017 a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a NATIONAL CERVICAL CANCER SCREENING PROGRAMME Monitor

More information

CERVICAL SCREENING WALES

CERVICAL SCREENING WALES CERVICAL SCREENING WALES Cervical Screening Wales Audit of Cervical Cancer (CSWACC) National Report 1999-2009 For more information about this report contact: Dr Rose Fox Director Cervical Screening Wales

More information

Northern Ireland cervical screening programme. Information for primary care and smear takers

Northern Ireland cervical screening programme. Information for primary care and smear takers Northern Ireland cervical screening programme Information for primary care and smear takers From January 2011, the Northern Ireland cervical screening programme will no longer invite women aged under 25

More information

TARGETS To reduce the age-standardised mortality rate from cervical cancer in all New Zealand women to 3.5 per or less by the year 2005.

TARGETS To reduce the age-standardised mortality rate from cervical cancer in all New Zealand women to 3.5 per or less by the year 2005. Cervical Cancer Key points Annually, around 85 women die from, and 230 women are registered with, cervical cancer. The decline in both incidence and mortality rates for cervical cancer has accelerated

More information

Scottish Cervical Screening Programme. Colposcopy and Programme Management

Scottish Cervical Screening Programme. Colposcopy and Programme Management Scottish Cervical Screening Programme Colposcopy and Programme Management Addendum to NHSCSP Publication No 20 Second Edition Exceptions Applicable in NHS Scotland April 2013 (Final Version 2.8 to incorporate

More information

07 August Dear Colleague,

07 August Dear Colleague, 07 August 2018 Dear Colleague, Further to our letter dated 9 May 2018, we are writing today to all healthcare professionals registered with CervicalCheck with updated advice and information regarding CervicalCheck.

More information

EFCS Symposium. Is cervical cancer screening based on HPV testing with cytology triage as safe as perceived?

EFCS Symposium. Is cervical cancer screening based on HPV testing with cytology triage as safe as perceived? EFCS Symposium Is cervical cancer screening based on HPV testing with cytology triage as safe as perceived? Amanda Herbert Guy s & St Thomas NHS Foundation Trust Is cervical cancer screening based on HPV

More information

Bleeding symptoms and subsequent risk of gynecological and other cancers

Bleeding symptoms and subsequent risk of gynecological and other cancers Acta Obstet Gynecol Scand 1998; 77: 564 569 Copyright C Acta Obstet Gynecol Scand 1998 Printed in Denmark all rights reserved Acta Obstetricia et Gynecologica Scandinavica ISSN 0001-6349 ORIGINAL ARTICLE

More information

Quantification of the effect of mammographic screening on fatal breast cancers: The Florence Programme

Quantification of the effect of mammographic screening on fatal breast cancers: The Florence Programme British Journal of Cancer (2002) 87, 65 69 All rights reserved 0007 0920/02 $25.00 www.bjcancer.com Quantification of the effect of mammographic screening on fatal breast cancers: The Florence Programme

More information

Effectiveness of opportunistic screening for cancer of the cervix uteri

Effectiveness of opportunistic screening for cancer of the cervix uteri Original Article Effectiveness of opportunistic screening for cancer of the cervix uteri Roderick Busuttil, Miriam Dalmas, Albert Cilia Vincenti Abstract The incidence and mortality of uterine cervical

More information

CERVICAL SCREENING WALES CERVICAL SCREENING PROGRAMME, WALES: 2001/02

CERVICAL SCREENING WALES CERVICAL SCREENING PROGRAMME, WALES: 2001/02 CERVICAL SCREENING WALES INFORMATION TEAM STATISTICAL REPORT CERVICAL SCREENING PROGRAMME, WALES: 2001/02 For more information about this report contact: Helen Beer, Information Analyst / Manager, Screening

More information

14. Cancer of the Cervix Uteri

14. Cancer of the Cervix Uteri KEY FACTS 14. Cancer of the Cervix Uteri ICD-9 180 On average 78 cases of invasive cervical cancer were registered per year. Half of cases occurred under 49 years of age. 2% of female cancers. Higher than

More information

Cuid d Fheidhmeannacht na Seirbhíse Sláinte. Part of the Health Service Executive. CS/PR/PM-20 Rev 2 ISBN Programme Report 2014/2015

Cuid d Fheidhmeannacht na Seirbhíse Sláinte. Part of the Health Service Executive. CS/PR/PM-20 Rev 2 ISBN Programme Report 2014/2015 Programme Report 2014/2015 Contents Summary points 2 Introduction to the statistics 2014/2015 3 Part 1 Cervical screening activity 3 Programme coverage 4 Laboratory turnaround time 7 Notification of results

More information

King s Research Portal

King s Research Portal King s Research Portal DOI: 10.1111/cyt.12259 Document Version Publisher's PDF, also known as Version of record Link to publication record in King's Research Portal Citation for published version (APA):

More information

Pathways to diagnosis of cervical cancer: screening history, delay in follow up, and smear reading

Pathways to diagnosis of cervical cancer: screening history, delay in follow up, and smear reading DOI: 10.1111/j.1471-0528.2006.01207.x www.blackwellpublishing.com/bjog Gynaecological oncology Pathways to diagnosis of cervical cancer: screening history, delay in follow up, and smear reading P Priest,

More information

Kent Academic Repository

Kent Academic Repository Kent Academic Repository Full text document (pdf) Citation for published version Lim, Anita W. W. and Ramirez, Amanda J. and Hamilton, William and Sasieni, Peter and Patnick, Julietta and Forbes, Lindsay

More information

Audit. Public Health Monitoring Report on 2006 Data. National Breast & Ovarian Cancer Centre and Royal Australasian College of Surgeons.

Audit. Public Health Monitoring Report on 2006 Data. National Breast & Ovarian Cancer Centre and Royal Australasian College of Surgeons. National Breast & Ovarian Cancer Centre and Royal Australasian College of Surgeons Audit Public Health Monitoring Report on 2006 Data November 2009 Prepared by: Australian Safety & Efficacy Register of

More information

POLICY FOR CLINICAL AUDIT OF NEW CASES OF INVASIVE CERVICAL CANCER AND DISCLOSURE OF RESULTS

POLICY FOR CLINICAL AUDIT OF NEW CASES OF INVASIVE CERVICAL CANCER AND DISCLOSURE OF RESULTS POLICY FOR CLINICAL AUDIT OF NEW CASES OF INVASIVE CERVICAL CANCER AND DISCLOSURE OF RESULTS Reference Number Version: Status Author: Alison Cropper CL-CP/2009/010 V3 Final Job Title: Hospital Based Programme

More information

National Cervical Screening Programme. Annual Report 2014

National Cervical Screening Programme. Annual Report 2014 National Cervical Screening Programme Annual Report 2014 Report prepared February 2017 Revised May 2017 Finalised June 2017 Report prepared by Megan Smith, Leanne Rumlee and Karen Canfell. Cancer Research

More information

Cervical cancer screening in Norway

Cervical cancer screening in Norway Cervical cancer screening in Norway «The future of cancer screening in Estonia: health benefits and best practices» 17 November 2016, Tartu Stefan Lönnberg Cancer Registry of Norway Screening governance

More information

KC53/61/65 Statistical Report Adroddiad Ystadegol 2012/13 Prepared by Cervical Screening Wales

KC53/61/65 Statistical Report Adroddiad Ystadegol 2012/13 Prepared by Cervical Screening Wales KC53/61/65 Statistical Report Adroddiad Ystadegol 2012/13 Prepared by Cervical Screening Wales CERVICAL SCREENING WALES STATISTICAL REPORT CERVICAL SCREENING PROGRAMME, WALES: 2012/2013 For more information

More information

Outcomes for women without conventional treatment for stage 1A (microinvasive) carcinoma of the cervix

Outcomes for women without conventional treatment for stage 1A (microinvasive) carcinoma of the cervix Aust N Z J Obstet Gynaecol 2018; 58: 321 329 DOI: 10.1111/ajo.12753 ORIGINAL ARTICLE Outcomes for women without conventional treatment for stage 1A (microinvasive) carcinoma of the cervix Charlotte Paul

More information

Estimating the efficacy of screening by auditing smear histories of women

Estimating the efficacy of screening by auditing smear histories of women Bridsh Journal of Cancer (1996) 73, 1001-1005 1996 Stockton Press All rights reserved 0007-0920/96 $12.00 M Estimating the efficacy of screening by auditing smear histories of women with and without cervical

More information

One of the commonest gynecological cancers,especially in white Americans.

One of the commonest gynecological cancers,especially in white Americans. Gynaecology Dr. Rozhan Lecture 6 CARCINOMA OF THE ENDOMETRIUM One of the commonest gynecological cancers,especially in white Americans. It is a disease of postmenopausal women with a peak incidence in

More information

Prognostic significance of positive lymph node number in early cervical cancer

Prognostic significance of positive lymph node number in early cervical cancer 1052 Prognostic significance of positive lymph node number in early cervical cancer JUNG WOO PARK and JONG WOON BAE Department of Obstetrics and Gynecology, Dong A University Hospital, Dong A University

More information

An audit of liquid-based cervical cytology screening samples (ThinPrep and SurePath) reported as glandular neoplasia

An audit of liquid-based cervical cytology screening samples (ThinPrep and SurePath) reported as glandular neoplasia DOI:10.1111/j.1365-2303.2009.00695.x An audit of liquid-based cervical cytology screening samples (ThinPrep and SurePath) reported as glandular neoplasia S. A. Thiryayi, J. Marshall and D. N. Rana Manchester

More information

Shared Care Pathway for Soft Tissue Sarcomas Presenting to Site Specialised MDTs. Gynaecological sarcomas Version 1

Shared Care Pathway for Soft Tissue Sarcomas Presenting to Site Specialised MDTs. Gynaecological sarcomas Version 1 Shared Care Pathway for Soft Tissue Sarcomas Presenting to Site Specialised MDTs Gynaecological sarcomas Version 1 Background This guidance is to provide direction for the management of patients with sarcomas

More information

Reasons why unscreened patients with cervical cancer present with advanced stage disease

Reasons why unscreened patients with cervical cancer present with advanced stage disease Reasons why unscreened patients with cervical cancer present with advanced stage disease Snyman LC, BMedSci, MBChB, MPraxMed, MMed(O&G), FCOG(SA), Principal Specialist Herbst U, MBChB, MMed(O&G), FCOG(SA),

More information

Health Board/Region: All-Wales

Health Board/Region: All-Wales Peer Review: Cancer Sub-site: Gynaecology Health Board/Region: All-Wales Cycle: Second Date of review: February 2018 This report describes the findings and themes observed by clinical review panels during

More information

WIRRAL UNIVERSITY TEACHING HOSPITAL CYTOLOGY NHS CERVICAL SCREENING PROGRAMME INFORMATION PACK FOR SAMPLE TAKERS

WIRRAL UNIVERSITY TEACHING HOSPITAL CYTOLOGY NHS CERVICAL SCREENING PROGRAMME INFORMATION PACK FOR SAMPLE TAKERS Author J. Evans BMS 3 Authoriser A. Bamber Page 1 of 16 WIRRAL UNIVERSITY TEACHING HOSPITAL CYTOLOGY NHS CERVICAL SCREENING PROGRAMME INFORMATION PACK FOR SAMPLE TAKERS Author J. Evans BMS 3 Authoriser

More information

COLPOSCOPY QUALITY IMPROVEMENT PROGRAM (C QuIP) VICTORIAN CERVICAL CYTOLOGY REGISTRY PILOT STUDY. Dorota Gertig, Marion Saville

COLPOSCOPY QUALITY IMPROVEMENT PROGRAM (C QuIP) VICTORIAN CERVICAL CYTOLOGY REGISTRY PILOT STUDY. Dorota Gertig, Marion Saville COLPOSCOPY QUALITY IMPROVEMENT PROGRAM (C QuIP) VICTORIAN CERVICAL CYTOLOGY REGISTRY PILOT STUDY Dorota Gertig, Marion Saville on behalf of the C QuIP Steering Committee June 2013 1 CONTENTS 1. Executive

More information

NHSCSP AUDIT OF INVASIVE CERVICAL CANCER: NATIONAL REPORT

NHSCSP AUDIT OF INVASIVE CERVICAL CANCER: NATIONAL REPORT NHSCSP AUDIT OF INVASIVE CERVICAL CANCER: NATIONAL REPORT 2009-2012 NHSCSP audit of invasive cervical cancer: national report 2009-2012 i Lead Authors Professor Peter Sasieni Professor of Biostatistics

More information

Pap Smear and Histopathological Study of Cervical Lesions

Pap Smear and Histopathological Study of Cervical Lesions Global Journal of Medical research: c Microbiology and Pathology Volume 14 Issue 4 Version 1.0 Year 2014 Type: Double Blind Peer Reviewed International Research Journal Publisher: Global Journals Inc.

More information

Efficacy of cervical intrarepithelial neoplasia (CIN)

Efficacy of cervical intrarepithelial neoplasia (CIN) The Ulster Medical Journal, Volume 72, No. 1, pp. 10-15, May 2003. Efficacy of cervical intrarepithelial neoplasia (CIN) treatment by cold coagulation A Zawislak, J H Price, H R McClelland, R G N Storey,

More information

Summary of the BreastScreen Aotearoa Mortality Evaluation

Summary of the BreastScreen Aotearoa Mortality Evaluation Summary of the BreastScreen Aotearoa Mortality Evaluation 1999 2011 Released 2015 nsu.govt.nz Citation: Ministry of Health. 2015. Summary of the BreastScreen Aotearoa Mortality Evaluation 1999 2011. Wellington:

More information

CANCER OUTCOMES AND SERVICES DIAGRAM IMPROVING ACCESS TO PSYCHOLOGICAL THERAPIES DIAGRAM SYSTEMIC ANTI-CANCER THERAPY DIAGRAM. Changed Description

CANCER OUTCOMES AND SERVICES DIAGRAM IMPROVING ACCESS TO PSYCHOLOGICAL THERAPIES DIAGRAM SYSTEMIC ANTI-CANCER THERAPY DIAGRAM. Changed Description Type: Data Dictionary Change Notice Reference: 1656 Version No: 1.0 Subject: NHS Data Model Update Effective Date: Immediate Reason for Change: Update of information Publication Date: 24 September 2018

More information

Questions and answers paper

Questions and answers paper Questions and answers paper From Monday, June 6 th 2016*, the age range for cervical screening will change from ages 20 60 years, to ages 25 64 years plus 364 days. The frequency of cervical screening

More information

A clinical review of borderline glandular cells reported on liquid-based cervical cytology

A clinical review of borderline glandular cells reported on liquid-based cervical cytology DOI: 10.1111/j.1471-0528.2009.02477.x www.bjog.org Gynaecological oncology A clinical review of borderline glandular cells reported on liquid-based cervical cytology A Patel, a N Thampy, b D Hemming, b

More information

Squamous cell carcinoma arising in a dermoid cyst of the ovary: a case series

Squamous cell carcinoma arising in a dermoid cyst of the ovary: a case series DOI: 10.1111/j.1471-0528.2007.01478.x www.blackwellpublishing.com/bjog Gynaecological oncology Squamous cell carcinoma arising in a dermoid cyst of the ovary: a case series JL Hurwitz, a A Fenton, a WG

More information

Experience of the Finnish mass screening system

Experience of the Finnish mass screening system British Journal of Preventive and Social Medicine, 1977, 31, 238-244 Selective screening for cervical cancer Experience of the Finnish mass screening system MATTI HAKAMA AND EERO PUKKALA From the Finnish

More information

Board Meeting Tuesday 17 August 2004 Board Paper No. 04/52 PUBLIC HEALTH ISSUE - GGNHSB CERVICAL SCREENING PROGRAMME - ANNUAL REPORT 2002/2003

Board Meeting Tuesday 17 August 2004 Board Paper No. 04/52 PUBLIC HEALTH ISSUE - GGNHSB CERVICAL SCREENING PROGRAMME - ANNUAL REPORT 2002/2003 EMBARGOED UNTIL MEETING Greater Glasgow NHS Board Board Meeting Tuesday 17 August 2004 Board Paper No. 04/52 DIRECTOR OF PUBLIC HEALTH PUBLIC HEALTH ISSUE - GGNHSB CERVICAL SCREENING PROGRAMME - ANNUAL

More information

Vagina. 1. Introduction. 1.1 General Information and Aetiology

Vagina. 1. Introduction. 1.1 General Information and Aetiology Vagina 1. Introduction 1.1 General Information and Aetiology The vagina is part of internal female reproductive system. It is an elastic, muscular tube that connects the outside of the body to the cervix.

More information

Preventing Cervical Cancer 2018 WHAT THIS WILL MEAN FOR PRIMARY CARE

Preventing Cervical Cancer 2018 WHAT THIS WILL MEAN FOR PRIMARY CARE Preventing Cervical Cancer 2018 WHAT THIS WILL MEAN FOR PRIMARY CARE DR GARY FENTIMAN, CLINICAL LEADER COLPOSCOPY, N C S P TAKE-HOME LESSONS Vaccination is Primary Prevention for Cervical Cancer Women

More information

Cytology Update M Laing QEUH

Cytology Update M Laing QEUH Cytology Update M Laing QEUH Age change to 25 to 65 Age 25 to 50 Three yearly smear invitation Age 50 to 65 Five yearly smear invitation Women on non routine screening will be invited up to age 70 OUTCOME

More information

cytology: perspective in the 1980s

cytology: perspective in the 1980s Cervical cancers diagnosed after negative results on cervical cytology: perspective in the 1980s Heather Mitchell, Gabriele Medley, Graham Giles Victorian Cytology (Gynaecological) Service, PO Box 253B,

More information

Chapter 8 Adenocarcinoma

Chapter 8 Adenocarcinoma Page 80 Chapter 8 Adenocarcinoma Overview In Japan, the proportion of squamous cell carcinoma among all cervical cancers has been declining every year. In a recent survey, non-squamous cell carcinoma accounted

More information

SIRI FORSMO,* BJARNE K JACOBSEN* AND HELGE STALSBERG t

SIRI FORSMO,* BJARNE K JACOBSEN* AND HELGE STALSBERG t International Journal of Epidemiology O International Epldemtologlcal Association 1996 Vol. 25, No. 1 Printed In Great Britain Cervical Neoplasia in Pap Smears: Risk of Cervical Intra-Epithelial Neoplasia

More information

Information Services Division NHS National Services Scotland

Information Services Division NHS National Services Scotland Cancer in Scotland October 2012 First published in June 2004, revised with each National Statistics publication Next due for revision April 2013 Information Services Division NHS National Services Scotland

More information

Department of Obstetrics and Gynecology, University Hospital Antwerpen, University of Antwerp, Antwerpen, Belgium.

Department of Obstetrics and Gynecology, University Hospital Antwerpen, University of Antwerp, Antwerpen, Belgium. Facts Views Vis Obgyn, 2015, 7 (2): 101-108 Original paper A cross-sectional, multicentre, epidemiological study on human papillomavirus (HPV) type distribution in adult women diagnosed with invasive cervical

More information

2. CANCER AND CANCER SCREENING

2. CANCER AND CANCER SCREENING 2. CANCER AND CANCER SCREENING INTRODUCTION The incidence of cancer and premature mortality from cancer are higher in Islington compared to the rest of England. Although death rates are reducing, this

More information

SCREENING FOR BOWEL CANCER USING FLEXIBLE SIGMOIDOSCOPY REVIEW APPRAISAL CRITERIA FOR THE UK NATIONAL SCREENING COMMITTEE

SCREENING FOR BOWEL CANCER USING FLEXIBLE SIGMOIDOSCOPY REVIEW APPRAISAL CRITERIA FOR THE UK NATIONAL SCREENING COMMITTEE SCREENING FOR BOWEL CANCER USING FLEXIBLE SIGMOIDOSCOPY REVIEW APPRAISAL CRITERIA FOR THE UK NATIONAL SCREENING COMMITTEE The Condition 1. The condition should be an important health problem Colorectal

More information

MasDA Mastectomy Decisions Audit 2015

MasDA Mastectomy Decisions Audit 2015 MasDA Mastectomy Decisions Audit 2015 AUDIT PROTOCOL FULL TITLE Mastectomy Decisions Audit: a prospective, multi-centre, population-based audit SHORT TITLE MasDA CHIEF INVESTIGATORS Mrs Jagdeep K Singh,

More information

Clinical statistics of gynecologic cancers in Japan

Clinical statistics of gynecologic cancers in Japan J Gynecol Oncol. 2017 Mar;28(2):e32 pissn 2005-0380 eissn 2005-0399 Review Article Clinical statistics of gynecologic cancers in Japan Wataru Yamagami, 1,7 Satoru Nagase, 2,7 Fumiaki Takahashi, 3 Kazuhiko

More information

Carcinoma of the breast in East Anglia : a changing pattern of presentation?

Carcinoma of the breast in East Anglia : a changing pattern of presentation? Journal oj'epidemiology and Community Health, 1978, 32, 178-182 Carcinoma of the breast in East Anglia 196-1975: a changing pattern of presentation? ANNE M. DE BONO AND E. M. KINGSLEY PILLERS From the

More information

The introduction of HPV testing to cervical screening in Scotland

The introduction of HPV testing to cervical screening in Scotland The introduction of HPV testing to cervical screening in Scotland Frequently asked questions for professionals Key messages From early 2020, cervical cytology (looking at cells under a microscope) will

More information

Awareness of cervical cancer and prevention among women eligible for cervical screening in Scotland

Awareness of cervical cancer and prevention among women eligible for cervical screening in Scotland Awareness of cervical cancer and prevention among women eligible for cervical screening in Scotland A project funded by the Scottish Government Screening Inequalities Fund Contents 1. Background... 2 2.

More information

CERVICAL CANCER FACTSHEET. What is cervical cancer?

CERVICAL CANCER FACTSHEET. What is cervical cancer? CERVICAL CANCER FACTSHEET What is cervical cancer? ENGAGe is releasing a series of factsheets to raise awareness of gynaecological cancers and to support its network to work at a grassroots level. Take-up

More information

HISTOLOGICAL TYPES OF UTERINE CANCER IN THE DR. SALVATOR VUIA CLINICAL OBSTETRICS AND GYNECOLOGY HOSPITAL ARAD DURING THE PERIOD

HISTOLOGICAL TYPES OF UTERINE CANCER IN THE DR. SALVATOR VUIA CLINICAL OBSTETRICS AND GYNECOLOGY HOSPITAL ARAD DURING THE PERIOD HISTOLOGICAL TYPES OF UTERINE CANCER IN THE DR. SALVATOR VUIA CLINICAL OBSTETRICS AND GYNECOLOGY HOSPITAL ARAD DURING THE 2000-2009 PERIOD Gheorghe Furău 1), Voicu Daşcău 1), Cristian Furău 1), Lucian

More information

Aneurin Bevan Health Board. Screening Programmes

Aneurin Bevan Health Board. Screening Programmes Aneurin Bevan Health Board Screening Programmes 1 Introduction The purpose of this report is to inform Board Members of the screening services offered nationally by Screening Services, Public Health Wales

More information

LLETZ (Large Loop Excision of the Transformation Zone) Fragmentation: Impact on Margin Assessment and Cervical Biopsy-LLETZ Correlation

LLETZ (Large Loop Excision of the Transformation Zone) Fragmentation: Impact on Margin Assessment and Cervical Biopsy-LLETZ Correlation LLETZ (Large Loop Excision of the Transformation Zone) Fragmentation: Impact on Margin Assessment and Cervical Biopsy-LLETZ Correlation Bridget Melley BSc. (Hons.) in Medical Science Galway-Mayo Institute

More information

SCREENING FOR CERVICAL CANCER BY PAP SMEAR

SCREENING FOR CERVICAL CANCER BY PAP SMEAR SCREENING FOR CERVICAL CANCER BY PAP SMEAR Pages with reference to book, From 229 To 231 Javaid H. Rizvi, Saadia Rasul, Basit Ghazali, Abid Jamal ( Department of Obstetrics and Gynaecology, The Aga Khan

More information

NHS public health functions agreement Service specification No.6 Meningococcal C (MenC) containing vaccine immunisation programme

NHS public health functions agreement Service specification No.6 Meningococcal C (MenC) containing vaccine immunisation programme NHS public health functions agreement 2018-19 Service specification No.6 Meningococcal C (MenC) containing vaccine immunisation programme 1 NHS public health functions agreement 2018-19 Service specification

More information

Partha Basu M.D. Screening Group/ Early Detection & Prevention Section

Partha Basu M.D. Screening Group/ Early Detection & Prevention Section Current Status of Quality Assured Colposcopy Practice in South Asia Partha Basu M.D. Screening Group/ Early Detection & Prevention Section Disclosures No financial disclosure NO conflict of interest to

More information

HPV-Negative Results in Women Developing Cervical Cancer: Implications for Cervical Screening Options

HPV-Negative Results in Women Developing Cervical Cancer: Implications for Cervical Screening Options HPV-Negative Results in Women Developing Cervical Cancer: Implications for Cervical Screening Options R. Marshall Austin MD,PhD Magee-Womens Hospital of University of Pittsburgh Medical Center (UPMC) (raustin@magee.edu)

More information

BRITISH COLUMBIA S CERVICAL CANCER SCREENING PROGRAM

BRITISH COLUMBIA S CERVICAL CANCER SCREENING PROGRAM BRITISH COLUMBIA S CERVICAL CANCER SCREENING PROGRAM DATE: NOVEMBER 19, 2016 PRESENTER: DR. DIRK VAN NIEKERK 1 Conflict of Interest Disclosure Nothing to disclose 2 ..in the beginning of the malady it

More information

Public Health Agency NORTHERN IRELAND BREAST SCREENING PROGRAMME ANNUAL REPORT & STATISTICAL BULLETIN QUALITY ASSURANCE REFERENCE CENTRE

Public Health Agency NORTHERN IRELAND BREAST SCREENING PROGRAMME ANNUAL REPORT & STATISTICAL BULLETIN QUALITY ASSURANCE REFERENCE CENTRE Public Health Agency Improving Your Health and Wellbeing NORTHERN IRELAND BREAST SCREENING PROGRAMME ANNUAL REPORT & STATISTICAL BULLETIN 2010-2011 QUALITY ASSURANCE REFERENCE CENTRE August 2012 1 2 Contents

More information

Trends in cancer of the cervix uteri in Sweden following cytological screening

Trends in cancer of the cervix uteri in Sweden following cytological screening Article no. bjoc.1999.0666 Trends in cancer of the cervix uteri in Sweden following cytological screening R Bergström 1,2, * P Sparén 2,3, * and H-O Adami 2,4 1 Department of Information Sciences, Division

More information

NHS Cervical Screening Programme in Kingston and Richmond ANNUAL REPORT

NHS Cervical Screening Programme in Kingston and Richmond ANNUAL REPORT Kingston Borough Team Richmond and Twickenham Borough Team 1. Introduction NHS Cervical Screening Programme in Kingston and Richmond ANNUAL REPORT 2010-12 All women between the ages of 25 and 64 are eligible

More information

Audit changes clinical practice! impact on rate of justification of hysterectomy indication

Audit changes clinical practice! impact on rate of justification of hysterectomy indication ecommons@aku Department of Obstetrics & Gynaecology Division of Woman and Child Health August 1995 Audit changes clinical practice! impact on rate of justification of hysterectomy indication Khalid S.

More information

Adjuvant Chemotherapy in High Risk Patients after Wertheim Hysterectomy 10-year Survivals

Adjuvant Chemotherapy in High Risk Patients after Wertheim Hysterectomy 10-year Survivals 6 Adjuvant Chemotherapy in High Risk Patients after Wertheim Hysterectomy 0-year Survivals V Sivanesaratnam,*FAMM, FRCOG, FACS Abstract Although the primary operative mortality following radical hysterectomy

More information

The routine use of ZedScan within one colposcopy service in England. MC Macdonald, R Lyon, JE Palmer, JA Tidy

The routine use of ZedScan within one colposcopy service in England. MC Macdonald, R Lyon, JE Palmer, JA Tidy The routine use of ZedScan within one colposcopy service in England MC Macdonald, R Lyon, JE Palmer, JA Tidy Introduction Colposcopic impression alone has been shown to be subjective with variable rates

More information

NORTHERN IRELAND BREAST SCREENING PROGRAMME ANNUAL REPORT & STATISTICAL BULLETIN

NORTHERN IRELAND BREAST SCREENING PROGRAMME ANNUAL REPORT & STATISTICAL BULLETIN Improving Your Health and Wellbeing NORTHERN IRELAND BREAST SCREENING PROGRAMME ANNUAL REPORT & STATISTICAL BULLETIN 211-212 QUALITY ASSURANCE REFERENCE CENTRE August 213 1 2 Contents Page Summary 4 Introduction

More information

Information on: HPV testing. jostrust.org.uk

Information on: HPV testing. jostrust.org.uk Information on: HPV testing jostrust.org.uk HPV testing This booklet covers: What is HPV? How do you get HPV? HPV testing Results of HPV testing Jo s Cervical Cancer Trust 2 What is HPV testing? Human

More information

Effect of margin status on cervical intraepithelial neoplasia recurrence following LLETZ in women over 50 years

Effect of margin status on cervical intraepithelial neoplasia recurrence following LLETZ in women over 50 years DOI: 10.1111/j.1471-0528.2008.01853.x www.blackwellpublishing.com/bjog Gynaecological oncology Effect of margin status on cervical intraepithelial neoplasia recurrence following LLETZ in women over 50

More information

Video Workshop Cervical cancer screening as a multidisciplinary process

Video Workshop Cervical cancer screening as a multidisciplinary process Video Workshop Cervical cancer screening as a multidisciplinary process Dr. Amanda Herbert (Guy s & St Thomas NHS Foundation Trust, London) Professor Jaroslava Duskova (Charles University, Prague, Czech

More information

THE NEW ZEALAND MEDICAL JOURNAL

THE NEW ZEALAND MEDICAL JOURNAL THE NEW ZEALAND MEDICAL JOURNAL Vol 8 No ISSN 75 876 Findings and outcome of teenage women referred for colposcopy at Christchurch Women s Hospital, New Zealand Peter Sykes, Dianne Harker, David Peddie

More information

following radiotherapy

following radiotherapy British Journal of Cancer (1995) 72, 1536-154 r) 1995 Stockton Press All rights reserved 7-92/95 $12. Serum tumour markers in carcinoma of the uterine cervix and outcome following radiotherapy ARM Sproston',

More information

RECLASSIFICATION OF CA CERVIX USING MUCIN STAINS AND ITS CLINICAL RELEVANCE

RECLASSIFICATION OF CA CERVIX USING MUCIN STAINS AND ITS CLINICAL RELEVANCE Original research article International Journal of Medical Science and Education pissn- 2348 4438 eissn-2349-3208 RECLASSIFICATION OF CA CERVIX USING MUCIN STAINS AND ITS CLINICAL RELEVANCE Dr Sudha Gupta

More information

Epidemiologic characteristics of cervical cancer in Korean women

Epidemiologic characteristics of cervical cancer in Korean women Review Article J Gynecol Oncol Vol. 25, No. 1:70-74 pissn 2005-0380 eissn 2005-0399 Epidemiologic characteristics of cervical cancer in Korean women Hyun-Joo Seol, Kyung-Do Ki, Jong-Min Lee Department

More information

EUROCHIP-II FINAL SCIENTIFIC REPORT ANNEX 08 REPORT OF ESTONIA

EUROCHIP-II FINAL SCIENTIFIC REPORT ANNEX 08 REPORT OF ESTONIA EUROCHIP-II FINAL SCIENTIFIC REPORT ANNEX 08 REPORT OF EUROCHIP-2 ACTION IN ESTONIA Impact of implementing a nationwide cervical cancer screening programme on population coverage by Pap-tests and on proportion

More information

Analysis of Prognosis and Prognostic Factors of Cervical Adenocarcinoma and Adenosqumous Carcinoma of the Cervix

Analysis of Prognosis and Prognostic Factors of Cervical Adenocarcinoma and Adenosqumous Carcinoma of the Cervix DOI 10.1007/s11805-009-0133-8 133 Analysis of rognosis and rognostic Factors of Cervical Adenocarcinoma and Adenosqumous Carcinoma of the Cervix Guangwen Yuan Lingying Wu Xiaoguang Li Manni Huang Department

More information

Trust Guideline for the inclusion of women at High Risk of Breast Cancer in the NHS Breast Screening Programme

Trust Guideline for the inclusion of women at High Risk of Breast Cancer in the NHS Breast Screening Programme Trust Guideline for the inclusion of women at High Risk of Breast Cancer in the NHS Breast Screening Programme For Use in: By: For: Division responsible for document: Key words: Name and job title of document

More information

Pretreatment tumour volume measurement on high-resolution magnetic resonance imaging as a predictor of survival in cervical cancer

Pretreatment tumour volume measurement on high-resolution magnetic resonance imaging as a predictor of survival in cervical cancer BJOG: an International Journal of Obstetrics and Gynaecology July 2004, Vol. 111, pp. 741 747 DOI: 10.1111/j.1471-0528.2004.00172.x Pretreatment tumour volume measurement on high-resolution magnetic resonance

More information

Ke Hu, Weiping Wang, Xiaoliang Liu, Qingyu Meng and Fuquan Zhang *

Ke Hu, Weiping Wang, Xiaoliang Liu, Qingyu Meng and Fuquan Zhang * Hu et al. Radiation Oncology (2018) 13:249 https://doi.org/10.1186/s13014-018-1197-5 RESEARCH Open Access Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma of cervix after

More information

Baseline HPV 2009: A route to evaluation of the HPV vaccination programme

Baseline HPV 2009: A route to evaluation of the HPV vaccination programme Baseline HPV 2009: A route to evaluation of the HPV vaccination programme Dr Sam Hibbitts Senior Lecturer in HPV Department of Obstetrics & Gynaecology School of Medicine Cardiff University Avian Papillomavirus

More information

receive adjuvant chemotherapy

receive adjuvant chemotherapy Women with high h risk early stage endometrial cancer should receive adjuvant chemotherapy Michael Friedlander The Prince of Wales Cancer Centre and Royal Hospital for Women The Prince of Wales Cancer

More information

Minimally Invasive Hysterectomies: A Survey of Current Practices. amongst members of the International Society for Gynaecologic Endoscopy

Minimally Invasive Hysterectomies: A Survey of Current Practices. amongst members of the International Society for Gynaecologic Endoscopy Minimally Invasive Hysterectomies: A Survey of Current Practices amongst members of the International Society for Gynaecologic Endoscopy Abstract Study Objective This study aimed to explore the current

More information

Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology

Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology bs_bs_banner doi:10.1111/jog.12596 J. Obstet. Gynaecol. Res. Vol. 41, No. 2: 167 177, February 2015 Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology

More information

United Kingdom and Ireland Association of Cancer Registries (UKIACR) Performance Indicators 2018 report

United Kingdom and Ireland Association of Cancer Registries (UKIACR) Performance Indicators 2018 report United Kingdom and Ireland Association of Cancer Registries (UKIACR) Performance Indicators 2018 report 20 June 2018 UKIACR Performance Indicators 2018 report 1 Contents Introduction... 3 Commentary for

More information

Annual report of Gynecologic Oncology Committee, Japan Society of Obstetrics and Gynecology, 2013

Annual report of Gynecologic Oncology Committee, Japan Society of Obstetrics and Gynecology, 2013 bs_bs_banner doi:10.1111/jog.12360 J. Obstet. Gynaecol. Res. Vol. 40, No. 2: 338 348, February 2014 Annual report of Gynecologic Oncology Committee, Japan Society of Obstetrics and Gynecology, 2013 Daisuke

More information

Treating cancer of the endometrium. Information for patients Gynaecology

Treating cancer of the endometrium. Information for patients Gynaecology Treating cancer of the endometrium Information for patients Gynaecology We have written this leaflet to provide you with information following your diagnosis of cancer of the endometrium. We understand

More information

Information Services Division NHS National Services Scotland

Information Services Division NHS National Services Scotland Cancer in Scotland April 2013 First published in June 2004, revised with each National Statistics publication Next due for revision October 2013 Information Services Division NHS National Services Scotland

More information

Ovarian Cancer Quality Performance Indicators

Ovarian Cancer Quality Performance Indicators Ovarian Cancer Quality Performance Indicators Patients diagnosed between October 2013 and September 2016 Publication date 20 February 2018 An Official Statistics publication for Scotland This is an Official

More information

CERVICAL POSTER ENGAGEMENT FEEDBACK

CERVICAL POSTER ENGAGEMENT FEEDBACK CERVICAL POSTER February 2018 Project Background Cervical cancer is the second most common cancer among women worldwide. Cervical screening can reduce cervical cancer deaths by: Finding and treating precancerous

More information

Commentary on NHS Digital. Retrospective Review of Surgery for Urogynaecological Prolapse and Stress Incontinence using Tape or Mesh, April 2018

Commentary on NHS Digital. Retrospective Review of Surgery for Urogynaecological Prolapse and Stress Incontinence using Tape or Mesh, April 2018 Commentary on NHS Digital. Retrospective Review of Surgery for Urogynaecological Prolapse and Stress Incontinence using Tape or Mesh, April 2018 Nick Black Professor of Health Services Research Policy

More information

Screening for Cervical Cancer in Europe

Screening for Cervical Cancer in Europe Asturias, 23 October, 2011 Asturias, 23 October Screening for Cervical Cancer in Europe M. Arbyn Unit Cancer Epidemiology, IPH, Brussels, Belgium Rue Juliette Wytsmanstraat 14 1050 Brussels Belgium T +32

More information